3Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma[J]. J Clin Oncol, 2007, 25(5): 571-578.
4Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5): 579-586.
5Jerusalem G, Warland V, Najjar F, et al. Whole-body ^18F-FDG PET for the evaluation of patients with Hodgkin' s disease and non-Hodgkin' s lymphoma[J]. Nucl Med Commun. 1999, 20(1): 13-20.
6Zinzani PL, Musuraca G, Alinari L, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma[J]. Clin Lymph Myeloma, 2007, 7(4): 291- 295.
7Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin' s disease[J]. Ann Hematol. 2006, 85: 759-767.
8Romer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose[J]. Blood, 1998, 91(12): 4464-4471.
9Haioun C, Itti E, Rahmouni A, et al. ^18Ffluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome[J]. Blood, 2005, 106(4): 1376-1381.
10Findling-Kagan S, Sivan H, Ostrovsky O, et al. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDRI[J]. Leuk Res, 2005, 29(4): 407-414.
